Gokul Agro Resources Limited's Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026.

Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses including Cenexi. The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing cost-efficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.

FY26 has been a year of steady operational progress and focused execution for Sanjivani Paranteral Limited. The commencement of commercial production at our newly established IV Fluid Infusion Plant in Pune marks a significant milestone in strengthening our manufacturing capabilities and expanding our healthcare product portfolio. Equipped with advanced technology and sustainable infrastructure, the facility is expected to improve operational efficiency, enhance product quality, and support growing demand across domestic and export markets. Our continued focus on quality manufacturing, disciplined cost management, and long-term customer relationships has enabled us to maintain stable business performance in a dynamic operating environment. This expansion further strengthens our market presence and positions the Company for scalable and sustainable long-term growth as we move into FY27. We remain committed to evaluating new growth opportunities and strategic initiatives aimed at enhancing operational scale and creating long-term value for all stakeholders.

Noida Toll Bridge Company Limited reported Standalone Profit after Tax attributable to Shareholders of Rs 390.28 Lakhs for Q4 FY26, a decrease compared to Rs 1,535.57 Lakhs in Q4 FY25.

We are happy to report that Solar Industries India Limited has delivered a landmark performance, clocking its highest-ever quarterly and annual sales of ₹3053cr and ₹9838cr respectively, despite no growth in domestic mining market. We have also achieved the highest ever quarterly EBIDTA & PAT at ₹870cr & ₹556cr registering growth of 59% & 61%yoy and highest ever yearly EBIDTA & PAT at ₹2750cr & ₹1737cr registering growth of 35% each in the year FY26. We achieved our EBITDA margin at around 28.51% for the quarter and 27.95% for the year. These numbers were propelled by strong sales from international and defence businesses, relentless focus on our high-value chain products and operational efficiencies.

Alembic Pharmaceuticals reported Q4 FY26 revenue from operations at ₹1,718.74 crore, marking a 9.43% year-on-year increase compared to Q4 FY25.

Standalone Profit After Tax (PAT) for FY26 increased by 116% year-on-year to ₹911 crore.

We are pleased to report a strong set of results for H2 FY26 and for the full financial year FY26. The consistent improvement across our key financial metrics — revenue, EBITDA, and PAT — is a testament to our focused execution on operational efficiency, product mix improvement, and disciplined capital allocation. During H2 FY26, Net Sales grew 35.2% year-on-year to INR 1,383.4 Mn, while EBITDA margins expanded by 45 basis points to 13.5%, reflecting our sustained focus on value-added product offerings and cost optimization initiatives across our manufacturing operations. PAT margins for the half year improved meaningfully by 97 basis points year- on-year to 7.2%, driven by strong operating leverage and controlled financing costs. On a full year basis, FY26 has been a landmark year for Kaka Industries. Net Sales crossed INR 2,632 Mn — a 33.1% growth over the prior year — while PAT surpassed INR 187 Mn, growing 46.0% year-on-year with PAT Margin expanding by 63 basis points to 7.1%. The full year EPS of Rs. 13.74 per share, representing a 45.9% growth over FY25, reflects the strong earnings accretion delivered to our shareholders. Looking ahead, we remain committed to sustaining this growth trajectory through continued investment in our product capabilities, capacity expansion, and strengthening our distribution and customer relationships. We are confident in our ability to deliver long-term, sustainable value to all stakeholders.

Mukta Agriculture Limited reported zero revenue from operations for both the quarter and the full financial year ended March 31, 2026.

Our overall performance for Q4'26 reflects a sequential growth of 12% and YoY growth of 40%. We recorded the highest Revenue, Gross margin & EBITDA in the last eight quarters. Notably, the Base business is already demonstrating superior profitability, operating at a ~26% EBITDA margin with gross margins of ~54% which reinforces the objective we established at the start of the year to pivot the business from a phase of reset to one defined by sustainable, profitable and reliable growth. However, we continue to be challenged by the Ibuprofen business which is demonstrating weak profitability, operating at a negative 21% EBITDA margin with gross margins of ~23%. Given the persistent headwinds on this business, we have appointed bankers to evaluate strategic options for this business to ensure optimal long-term value creation. Despite the significant crisis in the middle east and its impact on global business, the underlying fundamentals of the base business continue to remain strong, supported by a resilient operating model and a healthy product mix across regulated markets.